Evidence mapPaperPMID 42197247Full record

ReviewMolecules (Basel, Switzerland)2026

Galectin-3-A Multifunctional Molecule and a Key Player in Health and Disease.

Alina Lupu Surlea, Ticuta Negreanu-Pirjol, Laura Olariu, Bogdan-Stefan Negreanu-Pirjol, Sanda Jurja, Anca Cristina Lepadatu, Mihaela Basa, Natalia Rosoiu

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alina Lupu SurleaInstitute of Doctoral Studies, Doctoral School of Applied Sciences, Domain Biology, "Ovidius" University of Constanta, 58, Ion Voda Street, 900573 Constanta, Romania.
Ticuta Negreanu-PirjolFaculty of Pharmacy, "Ovidius" University of Constanta, 6, Capitan Aviator Al. Serbanescu Street, Campus, Building C, 900470 Constanta, Romania.ORCID 0000-0001-9254-1047
Laura OlariuAcademy of Romanian Scientists, Biological Sciences Section, 3, Ilfov Street, 050044 Bucharest, Romania.
Bogdan-Stefan Negreanu-PirjolFaculty of Pharmacy, "Ovidius" University of Constanta, 6, Capitan Aviator Al. Serbanescu Street, Campus, Building C, 900470 Constanta, Romania.
Sanda JurjaFaculty of Medicine, "Ovidius" University of Constanta, 1, University Alley, Campus, Building B, 900470 Constanta, Romania.
Anca Cristina LepadatuFaculty of Natural Sciences and Agricultural Sciences, "Ovidius" University of Constanta, 1, University Alley, Campus, Building B, 900470 Constanta, Romania.
Mihaela BasaMedical Analysis Laboratory, "Alexandru Gafencu" Military Emergency Hospital of Constanta, 96, Mamaia Bvd., 900527 Constanta, Romania.
Natalia RosoiuInstitute of Doctoral Studies, Doctoral School of Applied Sciences, Domain Biology, "Ovidius" University of Constanta, 58, Ion Voda Street, 900573 Constanta, Romania.ORCID 0009-0002-3687-1273

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Galectins are a family of proteins that belong to one of the most widespread classes of lectins found in all organisms. They are found intracellularly in various structures or secreted into the extracellular space, where they are involved in mediating cellular biological processes such as growth, function, interaction and response. They are known for their ability to bind to carbohydrates, specifically those containing beta-galactose. This narrative review outlines the human galectins, emphasizing Galectin-3, a β-galactoside-binding protein with numerous pleiotropic regulatory activities; it mediates various biological processes. Galectin-3 is an extensively studied member due to its broad implications in health and disease and we highlight the need for deeper insights into the molecular mechanisms and clinical implications of Galectin-3 as well as the context-dependent mechanisms through which Galectin-3 influences diverse physiological and pathological processes. Literature syntheses and scientific research, as well as clinical and experimental studies, were investigated regarding the biological and pathophysiological actions and implications of Galectin-3 in diseases. The study presents the structure, characteristics, roles, activities, and proinflammatory actions (as a mediator) and anti-inflammatory actions (as a modulator) of Galectin-3, as well as the main groups of diseases in which it is involved or associated with cardiovascular diseases, cancer, organ fibrosis, and metabolic diseases. The results emphasized the potential of Galectin-3 as an important molecule and highlighted the necessity for further research to improve its approach. This narrative review provides new insights into identifying its functions and the future development and rational design of Galectin-3-directed research strategies.

Indexed as

Galectin 3AnimalsBlood ProteinsCardiovascular DiseasesGalectinsHumansMetabolic DiseasesNeoplasmsBlood ProteinsGalectin 3GalectinsLGALS3 protein, humananti-inflammatorybiomarkerscancercardiovascular diseaseschronic diseasesGalectin-3galectinsproinflammatory

Identifiers

PMID42197247
PMCPMC13209898

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.